GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)
21 mai 2024 08h35 HE
|
GRI Bio, Inc.
Data presented at the 14th International Congress on Autoimmunity Encouraging preclinical data observed to date on par with OFEV® (nintedanib), a leading tyrosine kinase inhibitor with 2025...
Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
17 oct. 2023 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
In a Push to Limit Use of Glucocorticoids, US and EU5 Rheumatologists are Increasingly Turning to GSK’s Benlysta and AstraZeneca’s Saphnelo for the Treatment of Moderate-to-Severe Systemic Lupus Erythematosus, According to Spherix Global In
04 oct. 2023 03h00 HE
|
Spherix Global Insights
Exton, Pennsylvania, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Prior to the initial approval of Benlysta in 2011, systemic lupus erythematosus (SLE) patients and prescribers had limited options for the...
GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models
07 août 2023 08h35 HE
|
GRI Bio, Inc.
Data presented at The Autoimmunity Conference hosted by the Federation of American Societies for Experimental Biology (FASEB) GRI-0803 in development with an initial focus on the treatment...
Systemic Lupus Erythematosus Market Size Growing at 7% CAGR, Set to Reach USD 3,517 Million By 2030
01 mars 2023 10h00 HE
|
Acumen Research and Consulting
LOS ANGELES, March 01, 2023 (GLOBE NEWSWIRE) -- The Global Systemic Lupus Erythematosus Market Size accounted for USD 1,951 Million in 2021 and is estimated to achieve a market size of USD 3,517...
The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results for Biogen’s Litifilimab (BIIB059) in Lupus
07 sept. 2022 17h45 HE
|
Biogen Inc.
Part A results from the two-part Phase 2 LILAC study show litifilimab significantly reduced disease activity based on active joint count in people with systemic lupus erythematosus (SLE) compared to...
The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
28 juil. 2022 07h30 HE
|
Biogen Inc.
Results from Phase 2 LILAC study showed litifilimab significantly reduced skin disease activity in people with cutaneous lupus erythematosus (CLE) compared to placebo as measured by the primary...
Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight
09 févr. 2022 13h00 HE
|
DelveInsight Business Research LLP
Las Vegas, USA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight Systemic Lupus Erythematosus pipeline involves 70+ key...
Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
17 juin 2021 07h30 HE
|
Biogen Inc.
Global Phase 3 TOPAZ-1 study will evaluate the efficacy and safety of BIIB059, as compared to placebo, in active systemic lupus erythematosus (SLE), a debilitating autoimmune disease which has limited...
Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE)
20 avr. 2021 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
First study to explore potential benefit of a cannabinoid receptor type 2 agonist in SLEStudy sponsored and funded by the National Institute of Allergy and Infectious Diseases through the Autoimmunity...